Stereotaxis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Stereotaxis, Inc. on May 6, 2014. The report primarily serves to disclose the Company's financial results for the first quarter of fiscal year 2014, which were detailed in a press release filed as Exhibit 99.1. Additionally, the filing reports a significant regulatory development regarding reimbursement in Japan.
Key Financial Metrics
The filing text incorporates financial results by reference to an attached press release (Exhibit 99.1) but does not explicitly state specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this 8-K document. Therefore, specific financial metrics are not available in the provided source text.
Material Changes and Other Events
- Japan Reimbursement Approval: In April 2014, the Japanese Ministry of Health, Labor and Welfare authorized a "technical fee" of 50,000 yen (approximately $500) for each procedure using the Niobe system.
- Reimbursement Structure: This fee is in addition to separately approved reimbursement for Niobe-compatible magnetic catheters and standard physician fee coverage.
- Context: This approval resulted from a biennial review of reimbursement coverage for C2 medical devices.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding future activities and performance. Management notes that these statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from projections. The Company explicitly states it does not intend to update or revise these forward-looking statements except as required by law. No specific financial guidance or outlook numbers are provided in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release) for specific Q1 2014 revenue, net income, and cash flow figures.
- Verify the implementation timeline and commercial impact of the new 50,000 yen technical fee in Japan.
- Assess the total reimbursement package in Japan, including the interaction between the new technical fee, catheter reimbursement, and physician fees.
- Examine the full list of risk factors referenced in the Company's other SEC filings to understand potential impacts on future performance.